Category

News
Lack of access to effective treatments is forcing blood cancer patients to take desperate measures 12 April 2018 Lack of funded access to life-extending treatments for multiple myeloma is causing some New Zealand patients to take desperate measures, including importing cheap, potentially less effective ‘knock-offs’ of the drug Lenalidomide from India, and in some cases...
Continue Reading
The IMF is very pleased to have established a partnership with AbbVie to conduct the largest, most comprehensive chart-review study of myeloma patients with the t(11;14) translocation evident on FISH (fluorescence in situ hybridization) testing of bone marrow myeloma cells. This landmark retrospective analysis assesses the 16-to-24-percent of myeloma patients harboring the t(11;14) translocation. The...
Continue Reading
Multiple Myeloma action month March 2018: Thanks to medical innovation, Multiple Myeloma patients are living longer than ever before. Multiple Myeloma (MM) is the second most commonly diagnosed blood cancer after non-Hodgkin lymphoma, yet few people know much about this deadly disease. The American Cancer Society’s estimates for multiple myeloma in the United States for...
Continue Reading
What’s New in Myeloma Treatment: a New Zealand Perspective Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson, spoke at our patient seminar on What’s New in Myeloma Treatment: a New Zealand Perspective. Watch the seminar here:  
Continue Reading
Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital spoke at our patient seminar on his recent work looking at multiple myeloma incidence and survival outcomes in New Zealand. Dr Chan has just delivered a paper on this at the Haematology Society of Australia and NZ’s annual scientific conference. Download the presentation...
Continue Reading
The Cancer Society is calling for major changes to cancer services to save lives. It says 2,500 more New Zealanders would have survived cancer if they’d lived across the ditch. The claim is based on cancer survival statistics in a new international report published last month in the Lancet. It shows the chances of surviving...
Continue Reading
Happy New Year & greetings to you all Patient seminars: save the date Auckland on 28 February at North Shore Hospital Auditorium Wellington on 8 March at Russell McVeagh, Data Dimension House Click here or visit our Facebook page for details. I’m delighted that Dr Robert Weinkove from CCDHB and the Malaghan Research Institute has...
Continue Reading
INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at Russell McVeagh, Level 24, Dimension Data House, 157 Lambton Quay RSVP by Friday 2 March to contact@multiplemyeloma.org.nz    
Continue Reading
INVITATION Patient Seminar: What’s New in Myeloma Treatment: a New Zealand Perspective  with Dr. Leanne Berkahn, Dr. Henry Chan, Dr. Phillip Insull, and Dr. David Simpson on 28 February, from 7 – 9pm (Network from 6.30pm) at North Shore Hospital Auditorium – Whenua Pupuke, Auckland RSVP to: contact@multiplemyeloma.org.nz  
Continue Reading
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients The duration of the study for the patients will include a period for screening of up to 3 weeks. Patients will continue study treatment until disease progression, unacceptable adverse reaction, patients’ wish or other reason of...
Continue Reading
1 10 11 12 13 14

Floor 7, 90 The Terrace
Wellington Central
New Zealand